• K J Freise, A K Jones, M E Verdugo, R M Menon, P C Maciag, and A H Salem.
• AbbVie Inc., North Chicago, Illinois, USA.
• Clin. Pharmacol. Ther. 2017 Dec 1; 102 (6): 970-976.

AbstractExposure-response analyses of venetoclax in combination with bortezomib and dexamethasone in previously treated patients with multiple myeloma (MM) were performed on a phase Ib venetoclax dose-ranging study. Logistic regression models were utilized to determine relationships, identify subpopulations with different responses, and optimize the venetoclax dosage that balanced both efficacy and safety. Bortezomib refractory status and number of prior treatments were identified to impact the efficacy response to venetoclax treatment. Higher venetoclax exposures were estimated to increase the probability of achieving a very good partial response (VGPR) or better through venetoclax doses of 1,200 mg. However, the probability of neutropenia (grade ≥3) was estimated to increase at doses >800 mg. Using a clinical utility index, a venetoclax dosage of 800 mg daily was selected to optimally balance the VGPR or better rates and neutropenia rates in MM patients administered 1-3 prior lines of therapy and nonrefractory to bortezomib.© 2017 American Society for Clinical Pharmacology and Therapeutics.

24 keywords...

hide…